We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Our key disease areas
Our focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, we hope to achieve life-changing benefits for patients.
We are at the forefront of lung cancer treatment. Learn how we are prioritising precision medicine to deliver medicines matched to the patients who can best benefit from them in early stages – where we aim to help patients live longer and cancer-free – to late stages, where we look to meaningfully extend survival.
We have a long history in breast cancer and have always followed the science in providing innovative treatments. The way in which breast cancer is classified is evolving, learn more about how we are redefining how we treat breast cancer in the future.
We are augmenting our commitment to ovarian cancer. Read more on our approach to using ground-breaking science to further our understanding of the many biomarkers involved in ovarian cancer and how new therapies can be used to target these and improve outcomes.
We are pushing the boundaries of science to redefine care in haematology. Read more about our approach to tackling blood cancers, a diverse and complex family of diseases, and our commitment to delivering a meaningful impact on care, shaped by patient insights.
We have a personalised approach to prostate cancer. Learn more about the role that genetics and biomarkers can play in this disease and how our personalised approach is combatting these features of prostate cancer.
We are exploring novel immunotherapy combinations for overcoming the drivers of immunosuppression involved in liver cancer. Read more about our ambition to improve survival for these patients who are in urgent need of new effective treatments.
We are leading the revolution in pancreatic cancer. Learn more about this hard to detect cancer and how our ongoing research into the biomarkers involved has given rise to improved understanding and targeted therapies.
We are targeting cervical cancer with cure in mind. Learn more about how we are working to help turn the tide against cervical cancer by providing the immune system with tools to recognise and respond to the presence of tumour cells that our innate immune surveillance mechanisms may have missed.
In the spotlight
Meet our team
Be among colleagues who are driven by our passion, our people and a culture of innovation. We value courage, curiosity, collaboration, and a passion for learning. We encourage disruptive thinking where failure is an opportunity to learn – having the freedom to take risks without fear of failure.
Lynparza in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
Enhertu demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
Imfinzi and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
Veeva ID: Z4-34100
Date of Prep: June 2021